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The interaction between Avelox and bovine serum albumin (BSA) was investigated at diﬀerent temperatures by ﬂuorescence
spectroscopy. Results showed that Avelox could quench the intrinsic ﬂuorescence of BSA strongly, and the quenching mechanism
was a static quenching process with F¨ orester spectroscopy energy transfer. The electrostatic force played an important role on
the conjugation reaction between BSA and Avelox. The order of magnitude of binding constants (Ka)w a s1 0 4, and the number
of binding site (n) in the binary system was approximately equal to 1. The binding distance (r) was less than 3nm and the
primary binding site for Avelox was located in subdomain IIA of BSA. Synchronous ﬂuorescence spectra clearly revealed that the
microenvironment of amino acid residues and the conformation of BSA were changed during the binding reaction. In addition,
the eﬀect of some antibiotics on the binding constant of Avelox with BSA was also studied.
1.Introduction
Most drugs are able to bind to plasma protein when they
entrance in blood plasma system of organism, and serum
albumin is the most abundant protein in blood plasma and
serves as a depot protein and transport protein for numer-
ous endogenous and exogenous compounds [1]. Generally
speaking, drugs could bind with serum albumin mostly
through the formation of noncovalent complexes reversibly.
The drug-protein complex can be regarded as a form of drug
in the biology temporary storage, it can eﬀectively avoid
drug elimination from metabolism so quickly that it can
maintainthetotalconcentrationandeﬀectiveconcentrations
of blood medicine in plasma. In addition, binding of drugs
to plasma proteins controls their free, active concentrations
and provides a reservoir for a longer action, the binding
of drugs is responsible for the protective role of albumin.
Therefore, interaction of a drug with, and competition for,
the binding sites on plasma proteins might strongly aﬀect its
distribution, elimination, as well as its pharmacodynamics
and toxic properties [2]. Competition between two drugs for
their binding to plasma protein can strongly aﬀect the drug
disposition of both drugs, with possible serious physiological
consequences. Binding parameters are indeed fundamental
factorsindeterminingtheoverallpharmacologicalactivityof
a drug, and in this context the determination of the binding
parameters of drugs to albumin has become essential to
understand their pharmacokinetic, pharmacodynamic, and
toxicological proﬁle.
Avelox is a new generation of ﬂuoroquinolone antibacte-
rial agents, which is used to treat a wide variety of bacterial
infections including pneumonia, sinusitis, and worsening
of chronic bronchitis (the structure is shown in Figure 1).
This medicine gradually played a signiﬁcant role in clinical
cure.Atpresent,themolecularinteractionsbetweenBSAand
manydrugshavebeeninvestigatedsuccessfullyinbiomedical
domain [3]. However, the interaction between Avelox and
BSA has not been investigated, especially the eﬀect of the
common antibiotics on the binding of drugs to BSA. In
this paper, we provided investigations on the interaction
of Avelox with BSA by ﬂuorescence spectroscopy under
physiological pH 7.40 as well as the eﬀect of the coexistent
drugs. This study is expected to provide important insight
intotheessence,potentialtoxicitybetweendrugsandprotein
in real terms, and can also provide a useful clinical reference
for future combination therapy.2 International Journal of Analytical Chemistry
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Figure 1: Chemical structure of Avelox.
2. Experimental
2.1. Apparatus. All ﬂuorescence spectra were recorded with
a Shimadzu RF-540 spectroﬂuorophotometer and a Hitachi
F-4500 spectroﬂuorophotometer. Absorption was measured
with an UV-vis recording spectrophotometer (UV-265 Shi-
madzu, Japan). All pH measurements were made with
a pHS-3C precision acidity meter (Leici, Shanghai). All
temperatures were controlled by a CS501 superheated water
bath (Nantong Science Instrument Factory).
2.2. Materials. Avelox (no less than 99.9% pure) was
obtained from monitor of Chinese veterinary medicine.
Bovine serum albumin (BSA, no less than 99% pure) was
purchased from Sigma Company. Warfarin (WF), Chlorphe-
niramine (CP), and digitoxin (DG) were all obtained from
Chinese Institute of Drug and Biological Products. Stock
solutions of BSA (1.0 × 10−4 M) and Avelox (2.0 × 10−3 M)
were prepared. And all the stock solutions were further
diluted as working solutions prior to use. All the common
antibiotics were diluted to 1.0 × 10−3 M. Tris-HCl buﬀer
solution containing NaCl (0.15M) was used to keep the pH
of the solution at 7.40. NaCl solution was used to maintain
the ionic strength of the solution. All other reagents were
of analytical grade, and all aqueous solutions were prepared
with newly double-distilled water and stored at 277K.
The ﬂuorescence intensities were corrected for the
absorption of excitation light and reabsorption of emitted
light to decrease the inner ﬁlter using the following relation-
ship [4]:
Fcor = Fobs ×e(Aex+Aem)/2,( 1 )
where Fcor and Fobs are the corrected and observed ﬂu-
orescence intensities, respectively. Aex and Aem are the
absorbance values of Avelox at excitation and emission
wavelengths, respectively. The ﬂuorescence intensity used in
this paper was corrected.
2.3. Procedures
2.3.1. Fluorescence Experiments. In a typical ﬂuorescence
measurement, 1.0mL of pH = 7.40 Tris-HCl, 1.0mL of
1.0 × 10−5 M BSA solution, and diﬀerent concentrations
of Avelox were added into a 10mL colorimetric tube,
successively. The samples were diluted to scaled volume
with water, mixed thoroughly by shaking, and kept static
for 15min at diﬀerent temperatures (293, 303, and 313K).
The excitation wavelength for BSA was 280nm (or 295nm),
with the excitation and emission slit widths set at 5nm. The
solution was subsequently scanned on the ﬂuorophotometer
and determined the ﬂuorescent intensity at 343nm. The
ﬂuorescence intensity of BSA without Avelox was used as F0.
Meanwhile, the ﬂuorescence intensity of compound without
single Avelox (FBSA−Avelox − FAvelox) was used as F because
Avelox has slight ﬂuorescence emission at 343nm. The
ﬂuorescence intensities in this paper were corrected by(1).
Otherwise,werecordedtheﬂuorescencespectrawhentheΔλ
value between the excitation and emission wavelengths was
stabilized at 15 and 60nm, respectively.
2.3.2. Probe Displace Experiments. At 293K, diﬀerent con-
centrations of probe drug WF (or CP, DG) were respectively
addedtothemixtureofAvelox-BSAsystems.Themolarratio
of Avelox and BSA was kept at 1, both of their concentrations
are 1.0 × 10−6 M in BSA-Avelox systems. The mixtures
were diluted to scaled volume with water, mixed thoroughly
by shaking, and kept static for 30min. The excitation
wavelength for BSA was 280nm, with the excitation and
emission slit widths set at 5nm. The ﬂuorescence intensity of
BSA only with Avelox was used as F0 to study the quenching
eﬀect of probe drugs on Avelox-BSA system.
3. Results and Discussion
3.1. Interaction between Avelox and BSA. Based on
Section 2.3.1,w eh a v ed r a w nt h eﬂ u o r e s c e n c es p e c t r a
o fB S Aa sw e l la sd i ﬀerent Avelox added into BSA,
respectively. When the excitation wavelengths were at
280nm and 295nm, the emission peaks for BSA were both
located at 343nm. In this part, we also found that Avelox
had ﬂuorescence at 462nm obviously, but it had weak
ﬂuorescence at 343nm. According to this phenomenon,
we scanned the solution on the ﬂuorophotometer with the
range 300–450nm and recorded the ﬂuorescence spectra of
BSA-Avelox without Avelox which were shown in Figure 2.
As can be seen from Figure 2, the ﬂuorescence intensity of
BSA decreased regularly with the addition of Avelox, and
the maximum emission wavelength had 9nm red shifts
from 343nm to 352nm. This result implied that Avelox
could quench the intrinsic ﬂuorescence of BSA strongly,
and the interaction between Avelox and BSA resulted from
the formation of a ground-state complex between this drug
and protein. In addition, the UV absorption intensity of
Avelox which located at 336nm and 308nm decreased with
increased concentrations of BSA (as seen in Figure 3), it
could also reveal that the formation of new complex, in
addition suggested that the quenching was a static process.
3.2. Fluorescence Quenching Mechanism of BSA-Avelox Sys-
tem. Fluorescence quenching can occur by diﬀerent mech-
anisms, it may be dynamic quenching, resulting fromInternational Journal of Analytical Chemistry 3
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Figure 2: Fluorescence spectra of BSA-Avelox system. CBSA = 1.0 ×
10−6 M, 1∼16; CAvelox = (0.0, 1.0, 2.0, 4.0, 6.0, 8.0, 10.0, 12.5, 15.0,
20.0, 25.0, 30.0, 40.0, 50.0, 60.0, 70.0) × 10−6 M; (a) λex = 280nm;
(b) λex = 295nm; T = 293K.
the collisional encounter between the drug and protein,
or static quenching, resulting from the formation of a
ground-state complex between the drug and protein. Higher
temperature would result in faster diﬀusion and typically the
dissociation of weekly bound complexes, leading to larger
amount of dynamic quenching and smaller amounts of
static quenching, respectively [5]. In order to conﬁrm the
quenching mechanism, the ﬂuorescence quenching data are
analyzed by the Stern-Volmer equation [6]:
F0
F
= 1+Kqτ0[L] = 1+Ksv[L],( 2 )
where F0 and F are the ﬂuorescence intensities in the absence
and presence of ligand, respectively. τ0 is the average lifetime
of ﬂuorescence without ligand, which is about 10−8 s. Ksv
is the Stern-quenching constant. Kq is the quenching rate
constant of biomolecule, and [L] is the concentration of the
ligand. Based on the linear ﬁt plot of F0/F versus [L], the Kq
values can be obtained. The calculated results were shown
in Table 1. It appeared that the values of Ksv decreased with
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Figure 3:AbsorptionspectraofAvelox-BSAsystemFrom(1)to(6),
CAvelox = 1.0 × 10−5 M, CBSA =(0, 0.05, 0.1, 0.5, 0.8, 1.0) × 10−6 M,
(7): CBSA = 1.0 × 10−6 M.
the increase in temperature for all systems, which indicated
that the probable quenching mechanism of the interaction
between BSA and Avelox was initiated by complex formation
rather than by dynamic collision [7]. In addition, all the
values of Kq were much greater than the maximum scatter
collision quenching constant of various quenchers (2 ×
1010 M−1 s−1)[8].Thisalsosuggestedthatthequenchingwas
a static process [9].
For static quenching process, the relationship between
the ﬂuorescence intensity and the concentration of quencher
can be usually described by deriving (3)[ 10] to obtain the
binding constant (Ka) and the number of binging sites (n)i n
most of paper:
log

F0 −F
F

= nlogKa +nlog

[Dt] − n
F0 −F
F0
[Bt]

,
(3)
where [Dt]a n d[ Bt] are the total concentrations of Avelox
and protein, respectively. On the assumption that n in the
bracket is equal to 1, the curve of log(F0 − F)/F versus
log{[Dt] − [Bt](F0 − F)/F0} is drawn and ﬁtted linearly,
then the value of n can be obtained from the slope of the
plot. If the n value obtained is not equal to 1, then it is
substituted into the bracket and the curve of log(F0 − F)/F
versuslog{[Dt]−n[Bt](F0−F)/F0}isdrawnagain.Theabove
p r o c e s si sr e p e a t e da g a i na n da g a i nt i l ln obtained is only a
single value or a circulating value. Based on the n obtained,
the binding constant Ka can be also obtained. In the work, a
calculation program was developed. The calculation process
can be ﬁnished with calculator based on the simple program,
and the calculating results can be obtained by inputting F,
[Dt]a n d[ Bt]. The calculated results were shown in Table 1.
As seen in Table 1, the values of n were approximately
e q u a lt o1a td i ﬀerent temperatures, which indicated the
existence of just one main binding site in BSA for Avelox.
The order of magnitude of binding constants (Ka)w a s
104 indicating the existence of strong interaction between
BSA and Avelox. Meanwhile, the values of Ka decreased4 International Journal of Analytical Chemistry
Table 1: Quenching reactive parameters of BSA and Avelox at diﬀerent temperatures.
λex T/K Kq/(M−1 s−1) r1 Ka/(M−1) n r2
280
293 5.81 × 1012 0.9943 5.89 × 104 1.26 0.9971
303 5.49 × 1012 0.9938 5.75 × 104 1.23 0.9903
313 4.86 × 1012 0.9951 5.62 × 104 1.24 0.9913
295
293 6.35 × 1012 0.9956 6.02 × 104 1.18 0.9992
303 6.12 × 1012 0.9941 5.89 × 104 1.18 0.9937
313 5.54 × 1012 0.9960 5.75 × 104 1.43 0.9954
r1 is the linear relative coeﬃcient of F0/F ∼ [L]; r2 is the linear relative coeﬃcient of log(F0 −F)/F ∼ log{[Dt] −n[Bt](F0 −F)/F0}.
Kq is the quenching rate constant; Ka is the binding constant; n is the number of binding site.
with the increasing temperature, further suggested that the
quenching was a static process [11], hence it led to the
reduced of the stability of binary systems. On the other
hand, comparing the data of 280nm with 295nm, values
of Ka and n had less diﬀerence at diﬀerent temperatures, it
explained that Avelox would mainly quench the ﬂuorescence
of tryptophanyl residues from BSA.
3.3.TypeofInteractionForceoftheBinarySystems. Generally,
the interaction forces between the small drug molecule
and biological macromolecule include hydrogen bond, Van
der Waals force, electrostatic interactions, and hydrophobic
force [12] .R o s sa n dS u b r a m a n i a n[ 13]h a v ec h a r a c t e r i z e d
the sign and magnitude of the thermodynamic parameter,
enthalpy change (ΔH), free energy (ΔG), and entropy
change (ΔS) of reaction, associated with various individual
kinds of interaction. The reaction ΔH c a nb er e g a r d e da s
constant if the temperature changes little. Negative ΔH and
positive ΔS indicate that electrostatic interaction plays a
major role in the binding reaction. Positive ΔH and ΔS are
generally considered as the evidence for typical hydrophobic
interactions. In addition, Van der Waals force and hydrogen
bonding formation in low-dielectric media are characterized
by negative ΔH and ΔS [14]. The thermodynamic parame-
ters can be calculated on the basis of the following equations:
RlnK = ΔS −
ΔH
T
,( 4 )
ΔG = ΔH −TΔS. (5)
AccordingtothebindingconstantsKa ofAveloxtoBSAat
diﬀerent temperatures above (Table 1), the thermodynamic
parameterswereobtainedconveniently.Therefore,thevalues
of ΔH, ΔS, and ΔG were −1.79kJmol−1, 85.2Jmol−1 K−1,
and −26.8kJmol−1 (T = 293K), respectively. The negative
value of ΔG clariﬁed an automatic reaction between Avelox
and BSA. The negative value of ΔH and positive value of ΔS
showed that Avelox mainly bound to BSA by the electrostatic
attraction.
3.4. Identiﬁcation of the Binding Sites of Avelox on the
BSA. Participation of tyrosine (Tyr) and tryptophan (Trp)
groups in drug-serum albumin complexes is assessed using
diﬀerent excitation wavelengths. At 280nm wavelength, the
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Figure 4: Quenching curves of BSA-Avelox system at λex = 280nm
and 295nm CBSA = 1.0 × 10−6 M, CAvelox = 1.0 × 10−6 ∼ 1.2 ×
10−4 M; T = 293K.
Trp and Tyr residues in serum albumin are excited, whereas
the 295nm wavelength excites only Trp residues. In the
subdomains of BSA, IIA subunit (Trp and Tyr) and IIIA
(Tyr) are also considered as the main binding sites for small-
drug molecule [15]. Based on the Stern-Volmer equation,
comparing the ﬂuorescence quenching of protein excited at
280nm and 295nm allows to estimate the participation of
Trp and Tyr groups in the complex [16]. As seen in Figure 4,
the quenching curves of BSA excited at 280nm and 295nm
in the presence of Avelox overlap below the molar ratio
Avelox : BSA = 80:1. This means that if there are fewer than
80 Avelox molecules for 1 BSA molecules, only Trp residues
take part in the interaction of Avelox with BSA, and protein
ﬂuorescence was quenched by almost 80% at the molar ratio
80:1. The quenching of BSA ﬂuorescence exited at 280nm
above this molar ratio was slightly higher than that excited
at 295nm which means that Tyr residues began to take part
in the interaction. According to this conclusion, it could be
inferred that Avelox molecules only take interaction with Trp
residues of BSA at low concentration, whereas both Trp and
Tyr residues at high concentration, this conclusion can alsoInternational Journal of Analytical Chemistry 5
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Figure 5: Eﬀect of site maker probe on the ﬂuorescence intensities
of BSA-Avelox system CAvelox = CBSA = 1.0 × 10−6 M; CQ = (0.5, 1.0,
1.5, 2.0, 3.0, 4.0, 5.0) × 10−6 M. [Q]:  WF;  CP;  DG; λex =
280nm; T = 293K.
expoundwhythevalueofnisslightlymorethan1,whichhas
been shown in Table 1.
BSA has two Trp moieties (Trp-134 and Trp-212) located
in subdomains IB and IIA, respectively, and only Trp-
212 is located within a hydrophobic binding pocket of the
protein which usually bind many small ligands, especially
heterocyclic ligands of average size and small aromatic
carboxylic acids [17]. In this way, it could conﬁrm that the
primary binding site for Avelox was located in subdomain
IIA of BSA.
Site marker ﬂuorescent probes are useful for rapid
identiﬁcation of drug binding sites [18, 19]. In order to
estimate the drug binding sites on BSA, Sudlow et al. have
proposed the percentage of probe replacement method using
the following equation [20]:
probe displacement(%) =
F2
F1
×100. (6)
TheconcentrationsofBSAandAveloxwerekeptconstant
(1 × 10−6M), while that diﬀerent concentrations of various
probe drugs each were added into it. In the study of
the substitution reaction, F1 and F2 are the ﬂuorescence
intensities in the absence and presence probe drug. In this
paper, we have considered WF, CP, and DG as probe durgs
which bind speciﬁcally to sites I, II, and III, respectively. The
processed results were shown in Figure 5 by (6).
As seen in Figure 5, relative ﬂuorescence intensities
decreased obviously with increasing concentration of WF,
whereas it almost kept constant with the adding of CP and
DG. It indicated that Avelox was pronouncedly displaced by
WF rather than CP or DG, hence it could be inferred that
the binding site for Avelox was site I which located in sub-
domain IIA of BSA.
Atroomtemperature(293K),controltheconcentrations
of BSA and various probe drugs each at 1 × 10−6 M. Accord-
ing to the method described in Section 2.3.1, successively
adding diﬀerent concentrations of Avelox. The experimental
Table 2: Hill’s coeﬃcients nH of BSA-Avelox at diﬀerent tempera-
tures.
T/K λex/280nm λex/295nm
nH r3 nH r3
293 0.89 0.9938 0.86 0.9932
303 0.74 0.9959 0.72 0.9953
313 0.70 0.9913 0.69 0.9906
r3 is the linear relative coeﬃcient of lg[Y/(1 −Y)] ∼ lg[L].
data was calculated by (3). The values of binding constants
Ka were 4.68 × 104,5 . 5 0× 104,and 5.37 × 104 M−1in
presence of WF, CP, and DG, respectively. Compared with
the binding constant of Avelox-BSA without any probe drug
(5.89 × 104 M−1), it can be seen that the binding constant
between Avelox and BSA decreased most obviously in the
presence of WF, this result indicated that binding of Avelox
with BSA was aﬀected by adding WF, which compete the
same binding site of BSA. Hence, it also can be proposed that
the binding of Avelox primarily occurred in sub-domain IIA
(site I).
3.5. Hill’s Coeﬃcient of BSA-Avelox System. In biochem-
istry, the binding of a ligand molecule at one site of a
macromolecule often inﬂuences the aﬃnity for other ligand
molecules at additional sites. This is known as cooperative
binding. It is classiﬁed into positive cooperativity, negative
cooperativity,andnoncooperativityaccordingtothepromo-
tion or inhibition to the aﬃnity for other ligand molecules.
Hill’s coeﬃcient provides a way to quantify this eﬀect and is
calculated graphically on the basis of the following equation
[21]:
lg
Y
1 −Y
= lgK +nHlg[L],( 7 )
whereY is the fractional binding saturation; K is the binding
constant and nH is the Hill’s coeﬃcient. Hill’s coeﬃcient
is greater than one, which exhibits positive cooperativity.
Conversely, Hill’s coeﬃcient is less than one, which exhibits
negative cooperativity. A coeﬃcient of 1 indicates non-
cooperative reaction.
For ﬂuorescence measurement:
Y
(1 −Y)
=
Q
(Qm −Q)
,( 8 )
where Q = (F0 − F)/F0;1 /Qm = intercept of the plot 1/Q
versus 1/[L].Hill’scoeﬃcientswerepresentedinTable 2.The
values of nH were slightly less than 1 in the systems, both
at excitation wavelengths 280nm and 295nm at diﬀerent
temperatures, which indicated negative cooperativeness in
the interaction of Avelox with BSA, but they were weak.
In addition, the values of nH were inversely correlated with
increasing temperature illustrating the existence of negative
cooperativity between Avelox and BSA, that was, the ability
of drug bounding to BSA has decreased with the previous
ligand (Avelox) bounding to BSA gradually. Furthermore,
this negative cooperativity became more powerful with6 International Journal of Analytical Chemistry
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Figure 6: Fluorescence emission spectra for BSA(1) and UV
absorbance spectra for Avelox(2). CAvelox = CBSA = 6.0 × 10−6 M;
T = 293K.
increasing temperature, reducing the amount of Avelox that
could be bound to BSA. It was also one of the reasons which
led to the reduced Ka with increasing temperature.
3.6. Binding Distances between Avelox and BSA. Fluorescence
energy transfer is categorized as radiation energy transfer
andnonradiationenergytransfer.Theﬂuorescencespectrum
will deform if radiation energy transfer occurred. The ﬂuo-
rescence spectrum in Figure 2 has no deformation, thus the
energy transfer of BSA and Avelox should be nonradiation
energy transfer.
According to F¨ orster’s nonradiative energy transfer the-
ory, energy eﬃciency E, critical energy-transfer distance
R0(E = 50%), theenergy donor, the energyacceptordistance
r, the overlap integral, between the ﬂuorescence emission
spectrum of the donor, and the absorption spectrum of the
acceptor J can be calculated by the formulas [22]:
E = 1 −
F
F0
=
R6
0 
R6
0 +r6
,( 9 )
R6
0 = 8.78 ×10−25K2ΦN−4J, (10)
J =

F(λ)ε(λ)λ4Δλ

F(λ)Δλ
, (11)
where K2 is the orientation factor, Φ is the ﬂuorescence
quantum yield of the donor, N is a refractive index of
the medium, F(λ) is the ﬂuorescence intensity of the
ﬂuorescence donor at wavelength λ,a n dε(λ) is the molar
absorption coeﬃcient of the acceptor at this wavelength.
The overlap of UV-vis absorption spectra of Avelox and the
ﬂuorescence emission spectra of BSA (λex = 280nm) were
shown in Figure 6. Under these experimental conditions,
it has been reported that K2 = 2/3, N = 1.336, and
Φ = 0.118 [23]. Thus J, E, R0,a n dr were calculated
and shown in Table 3. The donor-to-acceptor distance r<
7nm indicated that the energy transfer from BSA to Avelox
Table 3: Parameters of E, J, r,a n dR0 between Avelox and BSA at
diﬀerent temperatures.
T/K E (%) J/(M−1cm3) R0/nm r/nm
293 28.04 1.07×10−14 2.48 2.90
303 26.66 1.04×10−14 2.47 2.92
313 25.60 1.02×10−14 2.46 2.95
R0 is the critical distance when E is 50%; r is the distance between acceptor
and donor; J is the overlap integral between the ﬂuorescence emission
spectrum of donor and the absorption spectrum of the acceptor.
occured with high possibility [24]. Furthermore, the value
of r was greater than R0 in this study which suggested that
Avelox could strongly quench the intrinsic ﬂuorescence of
BSA by a static quenching mechanism [25]. Moreover, the
distance r increased, and the energy eﬃciency E decreased
with increasing temperature (Table 3), which resulted in the
reduced stability of the binary systems and the values of Ka.
3.7. Conformation Investigation of BSA. Synchronous ﬂuo-
rescence spectra are used to investigate the protein confor-
mational change, as it has been shown to give narrow and
simple spectra. For the synchronous ﬂuorescence spectra
of protein, when the Δλ value between the excitation and
emission wavelengths is stabilized at either 15 or 60nm, the
synchronous ﬂuorescence gives characteristic information
for Tyr residues or Trp residues [26]. Because of the red
shifts of maximum emission wavelengths of both Tyr and
Trp with the less hydrophobic environment, blue shifts of
maximun emission wavelengths with the more hydrophobic
environment ocurr. These red or blue shifts indicated that
the conformation of BSA has been changed [27]. In order
to further study the eﬀect on the conformation of BSA, the
synchronous ﬂuorescence spectra were measured when the
Δλ = 15nm and Δλ = 60nm as shown in Figure 7.
I tc a nb es e e nf r o mFigure 7 that the ﬂuorescence
intensities of Tyr and Trp residues decreased regularly with
increasing concentration of Avelox. At the same time, the
maximum emission wavelength had 4nm blue shifts at the
investigated concentrations range when Δλ = 60nm, while
themaximumemissionwavelengthhad7nmredshiftswhen
Δλ = 15nm. This revealed that the aminoacids microen-
vironment changed due to the reaction of Avelox and BSA,
making the hydrophobicity of Trp residues strengthened,
whereas, the hydrophobic environment of Tyr residues more
polar. High concentration of drugs makes protein molecules
extend, thus reducing energy transfer between aminoacids,
reducing the ﬂuorescence intensity [28].
3.8. Eﬀect of the Coexistent Drugs on the Binding of Avelox
and BSA. According to this method about the percentage of
probe replacement method described in Section 3.4,w eh a v e
taken assays to study the eﬀects of some common antibiotics
on the binding of BSA-Avelox system. The concentrations
of BSA and Avelox were kept constant (1 × 10−6 M), while
that diﬀerent concentrations of various antibiotics each were
added into it. In the study of the substitution reaction, F1
and F2 are the ﬂuorescence intensities in the absence andInternational Journal of Analytical Chemistry 7
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Figure 7: Synchronous ﬂuorescence spectra of BSA-Avelox system CBSA = 1.0 × 10−6 M, 1 ∼ 6 CAvelox = (0.0, 2.0, 6.0, 10.0, 15.0, 25.0) ×
10−6 M; (a) Δλ = 15nm, (b) Δλ = 60nm; T = 293K.
presence of antibiotice. It supposed that there was no eﬀect
on the binding of BSA-Avelox system when the value of (F2−
F1)/F1 was less than ±5% by (6), that was, this antibiotice
could coexist with Avelox. The results showed that it allowed
500 times of gentamicin, thiamphenicol, 300 times of sul-
famethoxazole,erythromycinandstreptomycin,100timesof
ampicillin, neomycin and kanamycin, 20 times of penicillin
G sodium salt and acetyl spiramycin, and 10 times of cefo-
taxime sodium, cefoperazone sodium, ceftriaxone, and chlo-
ramphenicoltocoexistwithAvelox,butabitofciproﬂoxacin,
and norﬂoxacin could disturb the stability of BSA-Avelox
system, making the ﬂuorescence intensity change a lot. It
might result that Avelox and ciproﬂoxacin, norﬂoxacin all
belongtoaclassofdrugscalledquinoloneantibiotics,having
much similar structures, hence, there was certain competi-
tion among them for the protein. The competition would
lead to binding constant Ka change spontaneously. It could
be inferred that there were possible eﬀects on the stayed-
time from the blood, as well as plasma concentration and
eﬀectiveconcentration,havingeﬀectsontheeﬃcacyofdrugs
when the antibiotics such as ciproﬂoxacin and norﬂoxacin
coexistwithAveloxonthebindingreactionofBSA.However,
aminoglycosides, macrolides, sulfonamides, and penicillin
antibiotics have no eﬀects on the binary system, that is, those
antibioticswillnotaﬀectthetransportationofAveloxthough
BSA when they coexist with Avelox and also have no eﬀects
on the eﬃcacy of Avelox.
4. Conclusions
In this paper, the interaction of Avelox with BSA was
studied at diﬀerent temperatures by ﬂuorescence spectro-
scopic methods. The experimental results indicated that
Avelox molecular had embedded into the hydrophobic cavity
through electrostatic force and was mainly bound to Trp-
212 in BSA. The donor-to-acceptor distance r was less than
7nm, indicating nonradiation energy transfer. The negative
cooperativity existed in BSA-Avelox system for subsequent
ligand. From the synchronous ﬂuorescence spectra, it could
be shown that the quaternary conformational change of
BSA was induced by the interaction of Avelox with the Trp
microregion of BSA molecules. The method-like percentage
of probe replacement clearly revealed the existence of eﬀects
ofcommonantibiotics onthebinding ofBSA-Aveloxsystem.
The study will extend the use of ﬂuorescence spectroscopy;
meanwhile, it provides important insights into the future
clinical medicine.
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